Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Brigham Cancer Center has achieved remarkable ratings in stem cell transplantation, receiving a +1 score from the Center for International Blood & Marrow Transplant Research for both its adult and pediatric programs. This distinction recognizes their ability to surpass the expected one-year survival rate for allogeneic stem cell transplants in the U.S. Notably, this is the sixth consecutive year for the adult program and the first for the pediatric program, marking a significant achievement in patient care and multidisciplinary collaboration.
1. Dana-Farber received a +1 score from the CIBMTR for adult and pediatric stem cell programs. 2. This is the sixth year for the adult program and the second for pediatric. 3. Only 8 centers in the US outperformed in stem cell transplants. 4. Dana-Farber is the sole center exceeding survival benchmarks in the largest transplant centers. 5. The CIBMTR report assesses outcomes among 176 U.S. programs and adjusts for patient complexity. 6. Allogeneic transplants treat serious conditions like leukemias and lymphomas.
Listen Tab content
